TY - JOUR T1 - Initial Studies with <sup>11</sup>C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 807 LP - 813 DO - 10.2967/jnumed.119.231589 VL - 61 IS - 6 AU - Anat Biegon AU - Kenneth R. Shroyer AU - Dinko Franceschi AU - Jasbeer Dhawan AU - Mouna Tahmi AU - Deborah Pareto AU - Patrick Bonilla AU - Krystal Airola AU - Jules Cohen Y1 - 2020/06/01 UR - http://jnm.snmjournals.org/content/61/6/807.abstract N2 - Aromatase inhibitors are the mainstay of hormonal therapy in estrogen receptor–positive breast cancer, although the response rate is just over 50% and in vitro studies suggest that only two thirds of postmenopausal breast tumors overexpress aromatase. The goal of the present study was to validate and optimize PET with 11C-vorozole for measuring aromatase expression in postmenopausal breast cancer in vivo. Methods: Ten newly diagnosed postmenopausal women with biopsy-confirmed breast cancer were administered 11C-vorozole intravenously, and PET emission data were collected between 40 and 90 min after injection. Tracer injection and scanning were repeated 2 h after ingestion of 2.5 mg of letrozole. Mean and maximal SUVs and ratios to nontumor tissue in the contralateral breast were determined at baseline and after letrozole. Biopsy specimens from the same tumors were stained for aromatase using immunohistochemistry and evaluated for stain intensity and the percentage of immune-positive cells. Results: Seven of the 10 women (70%) demonstrated increased mean focal uptake of tracer (SUV ratio &gt; 1.1) coinciding with the mammographic location of the lesion, whereas the other 3 women (30%) did not (SUV ratio ≤ 1.0). All patients with an SUV ratio above 1.1 had mean SUVs above 2.4, and there was no overlap (SUV ratio ≤ 1; SUVmean, 0.8–1.8). The SUV ratio relative to breast around tumor was indistinguishable from the ratio to contralateral breast. Pretreatment with letrozole reduced tracer uptake in most subjects, although the percentage of blocking varied across and within tumors. Tumors with a high SUV in vivo also showed a high immunohistochemical staining intensity. Conclusion: PET with 11C-vorozole is a useful technique for measuring aromatase expression in individual breast lesions, enabling noninvasive quantitative measurement of baseline and posttreatment aromatase availability in primary tumors and metastatic lesions. ER -